CLINICAL TRIALS PROFILE FOR HEMANGEOL
✉ Email this page to a colleague
All Clinical Trials for HEMANGEOL
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT01222091 ↗ | Study on the Effect of a Beta Blocker on Increased Sensitivity to Pain in Humans Caused by Opioids | Completed | Stanford University | Phase 2 | 2009-02-01 | This research study explores whether a beta-blocker (propranolol) can prevent a person from becoming more sensitive to pain after administration of an opioid (remifentanil). Beta blockers inhibit the sympathetic (fight or flight) response and are often used to treat angina and high blood pressure. In a previous study in human volunteers, the investigators demonstrated an increased sensitivity to pain after a 60-minute infusion of the opioid remifentanil. The goal of this study is to identify a possible inhibitor of this phenomenon. |
| NCT02595996 ↗ | Propranolol Dose Escalation in Lymphedema in Patients | Terminated | Columbia University | Phase 2 | 2017-06-07 | This is a study to investigate the safety and efficacy of propranolol in the treatment of patients with primary lymphedema. The primary goal is to assess patient tolerability of increasing doses of propranolol. The secondary goal is to assess lymphedema symptoms and signs in response to propranolol treatment. |
| NCT02871349 ↗ | Trial of Propranolol in Children and Youth With Autism Spectrum Disorder and Predictors of Response | Completed | United States Department of Defense | Early Phase 1 | 2016-08-01 | The purpose of this study is to find out how the brain of people with autism is affected by Propranolol. Propranolol is not FDA approved for the treatment of autism. Propranolol is FDA approved for the treatment of heart conditions such as blood pressure This research is being done because there are currently no drug treatment options for language impairments and social difficulties often experienced by people with autism. |
| NCT02871349 ↗ | Trial of Propranolol in Children and Youth With Autism Spectrum Disorder and Predictors of Response | Completed | University of Missouri-Columbia | Early Phase 1 | 2016-08-01 | The purpose of this study is to find out how the brain of people with autism is affected by Propranolol. Propranolol is not FDA approved for the treatment of autism. Propranolol is FDA approved for the treatment of heart conditions such as blood pressure This research is being done because there are currently no drug treatment options for language impairments and social difficulties often experienced by people with autism. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for HEMANGEOL
Condition Name
Clinical Trial Locations for HEMANGEOL
Trials by Country
Clinical Trial Progress for HEMANGEOL
Clinical Trial Phase
Clinical Trial Sponsors for HEMANGEOL
Sponsor Name
